Here's why trafficking and entry remain key barriers to CAR T success in solid tumors.
- U.S. Pharma Tariffs And MFN Become Law After April 2 Update
- How To Implement Post-Approval Changes On A Global Level
- March 2026 — CDMO Opportunities And Threats Report
- Target Selection Drives The Future Of CAR T Therapy In Solid Tumors
- Mastering Biotech's Insourcing/Outsourcing Trade-Offs
- From Principles To Practice: Building Quality Into Generative AI-Assisted Pharma Operations
- Mitigating Challenges In Solid Tumor Delivery
- From QM To QMM For AI-Assisted Pharmaceutical Manufacturing Operations
CELL & GENE ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
Impact Of Media Selection
To highlight the importance of media selection, a study was conducted assessing the effect of three commercially available cGMP grade medias and their influence on T-cell phenotype.
-
Automated Sampling Of A Four Vessel Parallel CHO Cell Culture
Learn how automated sampling for parallel bioreactors enables continuous, sterile sample collection from CHO cell cultures, maintaining cell density with reduced manual intervention.
-
Small Volume ATMP Cryo-Freezing Strategies
Discover best practices for cryopreserving small-volume ATMPs, focusing on sterility, viability, and efficiency with advanced containers and packaging.
-
Navigating Commercial Logistics For CGTs: A Roadmap To Scalable, Patient-Centered Success
The commercialization of cell and gene therapies requires a precise and resilient logistics model that can adapt to rapid demand and global expansion while maintaining a patient-first approach.
-
Enhancing Preclinical Cell Therapy Development
Automation in cell therapy development boosts reproducibility, reduces error, and enhances yield. Learn how it’s reshaping preclinical workflows and accelerating clinical trial readiness.
-
Select The Best Analyte: A Guide To Effective Mycoplasma Testing
As you build a Mycoplasma testing strategy to ensure drug safety, there are three analyte types to choose from: live Mycoplasma, RNA, and genomic DNA, each offering distinct advantages.
-
Expansion Of Human Bone Marrow-Derived MSCs
Achieving over 870 million viable, quality mesenchymal stem/stromal cells is possible. This efficient cell culture method scales bone marrow-derived MSCs for clinical needs.
-
Perfusion Cell Line Development For Intensified Processes
The biopharmaceutical industry is transforming by shifting to continuous and intensified upstream bioprocesses, which are driven by evolving demands. Discover the key goals and innovations shaping this transition for modern healthcare.
-
Maximizing MSC Yield And Quality: A Comparative Media Study
Maximize mesenchymal stem cell (MSC) expansion with a simplified culture process. New data demonstrates a high-performance, xeno-free media that eliminates the need for coatings or media exchanges.
-
Set Your Cell And Gene Therapy Program Up For Success From Day One
Partner with a specialized CDMO early in your CGT development to ensure a streamlined path from discovery to successful commercialization, avoiding costly pitfalls and delays.
NEWSLETTER ARCHIVE
- 04.16.26 -- Cell & Gene Capabilities That You Need to Know
- 04.16.26 -- Prioritizing Quality, Fit, And Supplier Reliability In CGT Materials
- 04.15.26 -- Faster, More Efficient Cell & Gene Therapy Workflows with ddPCR
- 04.15.26 -- Mitigating Challenges In Solid Tumor Delivery
- 04.14.26 -- Innovation That's Redefining Aseptic Filling
CELL AND GENE CONTENT COLLECTIONS
While there are opportunities to scale, there are also manufacturing gaps, capacity issues, and production timelines that require improvement to do so. And then, of course, there’s cost. Because scale up and scale out are significant to everyone in the sector, we’ve curated insightful editorial that addresses the most important aspects of scalability.
More Content Collections